The relationship between sex hormones and the metabolic syndrome

Acta Biomedica

Volumn 81, Issue SUPPL. 1, 2010, Pages 79-84

  Lunenfeld, Bruno ^a  

^a BAR ILAN UNIVERSITY   (Israel)

Author keywords

Androgen deprivation; Diabetes; Metabolic syndrome; Testosterone

Indexed keywords

ANDROGEN; C REACTIVE PROTEIN; TESTOSTERONE;

ARTICLE; BLOOD; HUMAN; HYPOGONADISM; MALE; METABOLIC SYNDROME X;

ANDROGENS; C-REACTIVE PROTEIN; HUMANS; HYPOGONADISM; MALE; METABOLIC SYNDROME X; TESTOSTERONE;

EID: 77954949786     PISSN: 03924203     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Araujo AB, et al. J Clin Endocrinol Metab 2004; 89 (12): 5920-6.
2. Lunenfeld B, Nieschlag, E. Testosterone therapy in the aging male. Aging Mle 2007; 10: 139-53.
3. Bhasin S, et al. J Clin Endocrinol Metab 2006; 91 (6): 1995-2010.
4. Bjorntorp P. Abdominal obesity and the metabolic syndrome. Ann Med 1992; 24: 465-8.
5. Despres JP, Marette A. Relation of components of insulin resistance syndrome to coronary disease risk. Curr Opin Lipidol 1994; 5: 274-89.
6. Assmann G, Nofer JR, Schulte H. Cardiovascular risk assessment in metabolic syndrome: view from PROCAM. Endocrinol Metab Clin North Am 2004; 33: 377-92.
7. Mazza A, Morley JE. Metabolic syndrome and the older population. The aging Male 2007; 10: 3-8.
8. Gerald B. Phillips Relationship between Serum Sex Hormonesand Glucose, Insulin, and Lipid Abnormalities in Menwith Myocardial Infarction PNAS. 1977; 74: 1729-33.
9. Vermeulen A, Goemaere S, Kaufman JM. Sex hormones, body composition and aging. The Aging Male 1999; 2: 8-16.
10. Reaven G. Syndrome X: 10 years after. Drugs 1999; 58 (suppl 1): 19-20.
11. Ritchie SA, Ewart MA, Perry CG, Connell JM, Salt IP. TheRole of insulin and the adipocytokines in regulation of vascularendothelial function. Clin Sci (London) 2004; 107 (6): 519-32.
12. Laaksonen DE, Niskanen R, Purnonen K, et al. Testosterone and sex-hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care 2004; 27: 1036-41.
13. Mulligan, T Frick MF, Zuraw QC, Stemhagen A, MCWhirter C. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract 2006; 60 (7): 762-9.
14. Oh JY, Barrett-Connor E, Wedick NM, Wingard DL. Endogenous sex hormones and the development of type 2 diabetes in older men and women; The Rancho Bernardo study. Diabetes Care 2002; 25: 55-60.
15. Dandona P, Dhindsa S, Chaudhuri A, Bhatia V, Topiwala S. Hypogonadotrophic hypogonadism in type 2 diabetes. Aging Male 2008; 11 (3): 107-17.
16. Ding EL, Song Y, Malik VS, et al. Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systemic review and meta-analysis. JAMA 2006; 295: 1288-99.
17. Kupelian V, Page ST, Araujo AB, Travison TG, BremnerWJ, McKinlay JB. Low sex hormone-binding globulin, totaltestosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men. J Clin Endocrinol Metab 2006; 91 (3): 843-50.
18. Osuna JA, Gomez-Perez R, Arata-Bellabarba G, Villaroel V. Relationship between BMI, total testosterone, sex hormonebinding-globulin, leptin, insulin and insulin resistance in obese men. Arch Androl 2006; 52: 355-61.
19. Smith MR. Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer. Urology 2004; 63: 742-5.
20. Smith MR, Finkelstein JS, McGovern FJ, et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 2002; 87: 599-603.
21. Basaria S, Lieb J II, Tang AM, et al. Long-term effects of androgen deprivation therapy in prostate cancer patients. Clin Endocrinol (Oxf) 2002; 56: 779-86.
22. Smith MR, Lee H, Nathan DM. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab 2006; 91: 1305-8.
23. Yialamas MA, Dwyer AA, Hanley E, Lee H, Pitteloud N, Hayes FJ. Acute sex steroid withdrawal reduces insulin sensitivity in healthy men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab 2007; 92: 4254-9.
24. Dockery F, Bulpitt CJ, Agarwal S, Donaldson M, Rajkumar C. Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. ClinSci (Lond) 2003; 104: 195-201.
25. Basaria S, Muller DC, Carducci MA, Egan J, Dobs AS. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Cancer 2006; 106: 581-8.
26. Keating NL, O'Malley J, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006; 24: 4448-56.
27. Choong K& Basaria S Emerging cardiometabolic complications of androgen deprivation therapy The Aging Male 2010 in press
28. Wang C, Cunningham G, Dobs A, et al. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab 2004; 89: 2085-98.
29. Isidori AM, Giannetta E, Greco EA, et al. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin Endocrinol 2005; 63: 280-93.
30. Wang CM, Nieschlag E, Swerdloff RS, et al. (ISA, ISSAM, EAU, EAA and ASA recommendations: investigation, treatment and monitoring of late-onset hypogonadism in males. Aging Male 2009 12: 5-12.
31. Morimoto S, Mendoza-Rodri{dotless}guez CA, Hiriart M, Larrieta ME, VitalP, Cerbon MA. Protective effect of testosterone on early apoptotic damage induced by streptozotocin in rat pancreas. J Endocrinol 2005; 187: 217-24.
32. Kapoor D, Goodwin E, Channer KS, Jones TH. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol 2006; 154 (6): 899-906.
33. Boyanov MA, Boneva Z, Christov VG. Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male 2003; 6: 1-7.
34. Heufelder AE, Saad F, Bunck MC, Gooren L. Fifty-twoweek treatment with diet and exercise plus transdermal te-stosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone. J Androl 2009; 30 (6): 726-33.
35. Naharci MI, Pinar M, Bolu E, Olgun A. Effect of testosterone on insulin sensitivity in men with idiopathic hypogonadotropic hypogonadism. Endocr Pract 2007; 13: 629-35.
36. Pitteloud N, Hardin M, Dwyer AA, et al. Increasing insulin resistance is associated with a decrease in Leydig cell testosterone secretion in men. J Clin Endocrinol Metab 2005a; 90: 2636-41.